Literature DB >> 19362963

Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.

Mary L McMaster1, Sigurdur Y Kristinsson, Ingemar Turesson, Magnus Björkholm, Ola Landgren.   

Abstract

Waldenström's macroglobulinemia (WM) is associated with a precursor condition, monoclonal gammopathy of undetermined significance (MGUS) of immunoglobulin-M (IgM) type. The etiology of these conditions is unknown. Recent studies at the population level have provided new data regarding familial aggregation of these disorders and other B-cell malignancies. Studies of familial clusters of WM have demonstrated an increased frequency of IgM MGUS compared with the general population and have provided new data suggesting that the phenotypic spectrum might also include polyclonal gammopathy and hypoglobulinemia. While the preponderance of immunoglobulin abnormalities in relatives of WM cases involves IgM, other immunoglobulin types (IgG and IgA) might also be affected. Large collaborative studies are needed to confirm these findings, which present an opportunity to define the earliest lesion(s) in the WM oncogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362963      PMCID: PMC2722444          DOI: 10.3816/CLM.2009.n.003

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  22 in total

1.  Familial Waldenstrom's macroglobulinemia.

Authors:  Mary L McMaster
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  Chronic immune stimulation and subsequent Waldenström macroglobulinemia.

Authors:  Jill Koshiol; Gloria Gridley; Eric A Engels; Mary L McMaster; Ola Landgren
Journal:  Arch Intern Med       Date:  2008-09-22

3.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

4.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

5.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

6.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2008-08-13       Impact factor: 22.113

7.  Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.

Authors:  A Anagnostopoulos; A Evangelopoulou; D Sotou; D Gika; D Mitsibounas; M-A Dimopoulos
Journal:  Ann Hematol       Date:  2002-07-11       Impact factor: 3.673

8.  Transient paraproteinemia: an intriguing immunological anomaly.

Authors:  Stephen L Strobel
Journal:  Ann Clin Lab Sci       Date:  2003       Impact factor: 1.256

9.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

Authors:  Ola Landgren; Jerry A Katzmann; Ann W Hsing; Ruth M Pfeiffer; Robert A Kyle; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew A Adjei; Dirk R Larson; Angela Dispenzieri; L Joseph Melton; Lynn R Goldin; Mary L McMaster; Neil E Caporaso; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

10.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Shimera Kamihira; Masao Tomonaga
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

View more
  6 in total

1.  Pathophysiology of Waldenström's macroglobulinemia.

Authors:  Marvin J Stone; Virginia Pascual
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

2.  Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution.

Authors:  A J M Vermorken; J Zhu; W J M VAN DE Ven; Y Cui; J P Fryns
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

3.  The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.

Authors:  Christopher J Klein; Joon-Shik Moon; Michelle L Mauermann; Steven R Zeldenrust; Yanhong Wu; Angela Dispenzieri; Peter J Dyck
Journal:  Can J Neurol Sci       Date:  2011-03       Impact factor: 2.104

4.  Delayed Endovascular Stenting for Severe Vertebral Artery Stenosis with Precarious Thrombosis.

Authors:  Ali S Haider; Caleb Gottlich; Tijani Osumah; Maryam Alam; Umair Khan; Steven Vayalumkal; Dean Leonard; Richa Thakur; Kennith F Layton
Journal:  Cureus       Date:  2017-05-26

5.  Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees.

Authors:  Martha J Glenn; Michael J Madsen; Ethan Davis; Cassandra D Garner; Karen Curtin; Brandt Jones; Justin A Williams; Michael H Tomasson; Nicola J Camp
Journal:  Blood Cancer J       Date:  2019-02-26       Impact factor: 11.037

Review 6.  Impact of Adaptive Thermogenesis in Mice on the Treatment of Obesity.

Authors:  Marianela Bastías-Pérez; Sebastián Zagmutt; M Carmen Soler-Vázquez; Dolors Serra; Paula Mera; Laura Herrero
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.